LIMN (Liminatus Pharma, Inc. Class A Common Stock) Stock Analysis - Analyst Ratings

Liminatus Pharma, Inc. Class A Common Stock (LIMN) is a publicly traded Healthcare sector company. As of May 21, 2026, LIMN trades at $0.27 with a market cap of $8.40M and a P/E ratio of -0.43. LIMN moved -1.21% today. Year to date, LIMN is -72.50%; over the trailing twelve months it is -97.02%. Its 52-week range spans $0.16 to $33.66. Rallies surfaces LIMN's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.

What do analysts rate LIMN?

The average price target is $0.00.

LIMN Key Metrics

Key financial metrics for LIMN
MetricValue
Price$0.27
Market Cap$8.40M
P/E Ratio-0.43
EPS$-0.43
Dividend Yield0.00%
52-Week High$33.66
52-Week Low$0.16
Volume49.05M
Avg Volume0
Revenue (TTM)$0
Net Income$-10.21M
Gross Margin0.00%

LIMN Analyst Consensus

LIMN analyst coverage data. Average price target: $0.00.

Latest LIMN News

Common questions about LIMN

What do analysts rate LIMN?
The average price target is $0.00.
Does Rallies show LIMN price targets?
Yes. Rallies tracks LIMN analyst ratings, consensus rating, average price target, upgrades, downgrades, analyst firms, and recent price target changes when available.
Is LIMN research on Rallies investment advice?
No. Rallies provides research, data, and educational context for LIMN. It does not provide personalized investment advice.
LIMN

LIMN